“LEQEMBI[®] Intravenous Infusion” approved for the treatment of Alzheimer’s disease in Japan
Stockholm, September 25, 2023 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that “LEQEMBI[®] Intravenous Infusion” (200 mg, 500mg, lecanemab) has been approved in Japan as a treatment for slowing progression of mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease (AD). The regulatory approval in Japan announced today, entitles BioArctic to a milestone of EUR 17 M.LEQEMBI is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril[1]) and insoluble forms of Aβ. LEQEMBI is the